Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for NKX019 (CAR NK cell therapy) in Lupus nephritis. The expected timing is based on the latest available company guidance and may change.
Ntrust-1 trial. 10/17/23- IND clearance. 6/27/24- Initiated Ph1 trial. Q4 '24- First patient dosed in Nov 2024. 8/12/25- Preliminary clinical data in H2 2025. 11/10/25:- Ntrust-1 enrollment streamlined under combined iDSMB; second dose-escalation cohort enrolling; preliminary data expected 2026. 03/25/26:- Ntrust-1 enrollment ongoing; patients now dosed at 4B cells; initial data planned at 2026 medical conference. 04/15/26:- FDA agreed outpatient dosing and redosing for Ntrust-1. Initial data expected at 2026 medical meeting. 05/12/26:- Enrollment ongoing at 4B-dose in Ntrust-1; initial multi-indication data planned at 2026 medical meeting. 08/10/26:- Outpatient dosing underway; Ntrust-1 enrollment continues; initial data expected in 2026.
Verification
Confirm timing and program details against the company announcement or filing.